Argenx announces CEO transition
Source: SeekingAlpha
2026-01-05 07:46:14 ET
More on argenx SE
- Argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold
- argenx: Sights Set On $1,000
- argenx SE (ARGX) Q3 2025 Earnings Call Transcript
- Argenx cut to Neutral at Baird after trial setback for Vyvgart
- argenx to discontinue phase 3 UplighTED trials of efgartigimod in thyroid eye disease; stock drops
Read the full article on Seeking Alpha
For further details see:
Argenx announces CEO transition
Argen X SE
NASDAQ: ARGNF
ARGNF Trading
2.56% G/L:
$814.94 Last:
2 Volume:
$814.94 Open:
ARGNF Latest News
March 06, 2026 01:00:00 am
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
February 26, 2026 01:00:00 am
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026 12:30:00 am
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
ARGNF Stock Data
$50,515,067,402
49,738,024
N/A
478
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
